Heinrich Meier
Bayer Corporation
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Heinrich Meier.
Drug Discovery Today | 2006
Tobias Wunberg; Martin Hendrix; Alexander Hillisch; Mario Lobell; Heinrich Meier; Carsten Schmeck; Hanno Wild; Berthold Hinzen
Drug-like and lead-like hits derived from HTS campaigns provide good starting points for lead optimization. However, too strong emphasis on potency as hit-selection parameter might hamper the success of such projects. A detailed absorption, distribution, metabolism, excretion and toxicology (ADME-Tox) profiling is needed to help identify hits with a minimum number of (known) liabilities. This is particularly true for drug-like hits. Herein, we describe how to break down large numbers of screening hits and we provide a comprehensive overview of the strengths and weaknesses for each structural class. The overall profile (e.g. ligand efficiency, selectivity and ADME-Tox) is the distinctive feature that will define the priority for follow-up.
ChemMedChem | 2006
Mario Lobell; Martin Hendrix; Berthold Hinzen; Jörg Keldenich; Heinrich Meier; Carsten Schmeck; Rudolf Schohe-Loop; Tobias Wunberg; Alexander Hillisch
The need for inu2005silico characterization of HTS hit structures as part of a data‐driven hit‐selection process is demonstrated. A solution is described in the form of an inu2005silico ADMET traffic light and PhysChem scoring system. This has been extensively validated with in‐house data at Bayer, published data, and a collection of launched small‐molecule oral drugs.
Bioorganic & Medicinal Chemistry Letters | 2011
Klaus Urbahns; Takeshi Yura; Muneto Mogi; Masaomi Tajimi; Hiroshi Fujishima; Tsutomu Masuda; Nagahiro Yoshida; Toshiya Moriwaki; Timothy B. Lowinger; Heinrich Meier; Fiona Chan; David Madge; Jang Bahadur Gupta
We have identified naphthol derivatives as inhibitors of the vanilloid receptor TRPV1 by high throughput screening. The initial lead showed high clearance in rats and has been optimized by enhancing the acidity of the phenol group. Compound 6b has reduced clearance, improved potency and is active in rat cystometry models of urinary incontinence after intravenous administration.
Heterocycles | 2009
Daniel Meibom; Marcus Bauser; Heinrich Meier; Dirk Schneider; Niels Svenstrup; Dieter Haebich
An efficient synthesis of 3,7-disubstituted 3,5-dihydro-4H-pyrazolo-[4,3-d][1,2,3]triazin-4-ones (2), especially suited for late-stage decoration, is described. Diverse 3-benzyl analogs were obtained by amidation-cyclization in one pot and various pyrazolotriazinone-7-bromides were employed in Suzuki and Sonogashira cross-coupling reactions.
Journal of Pharmacology and Experimental Therapeutics | 2004
Jean De Vry; Dirk Denzer; Elke Reissmueller; Maud Eijckenboom; Markus Heil; Heinrich Meier; Frank Mauler
Archive | 2002
Takeshi Yura; Muneto Mogi; Yuka Ikegami; Tsutomu Masuda; Toshio Kokubo; Klaus Urbahns; Timothy B. Lowinger; Nagahiro Yoshida; Joachim Freitag; Heinrich Meier; Reilinde Nopper; Makiko Marumo; Masahiro Shiroo; Masaomi Tajimi; Keisuke Takeshita; Toshiya Moriwaki; Yasuhiro Tsukimi
Archive | 2002
Bettina Beyreuther; Michael Hahn; Christopher Kallus; Joachim Krüger; Heinrich Meier; Elke Reissmüller; Leila Telan; Reilinde Nopper; Mathias Kroll
Archive | 2004
Marcus Bauser; Joachim Krüger; Heinrich Meier; Verena Vöhringer; Bettina Beyreuther; Muneto Mogi; Makiko Marumo; Naoki Tsuno; Haruka Shimizu; Hiroshi Fujishima; Hiroaki Yuasa; Mayumi Hayashi; Masaomi Umeda; Atsuko Iwata
Archive | 2007
Heinrich Meier; Eckhard Dr. Bender; Ulf Brüggemeier; Ingo Flamme; Dagmar Karthaus; Peter Kolkhof; Daniel Meibom; Dirk Schneider; Verena Voehringer; Chantal Fürstner; Joerg Keldenich; Dieter Lang; Elisabeth Pook; Carsten Schmeck
Archive | 2001
Markus Heil; Heinrich Meier; Paul Naab; Arnd Voerste; Vry Jean-Marie-Viktor Dr. De; Dirk Denzer; Frank Mauler; Klemens Lustig; Jan-Bernd Lenfers